Daewoong Pharmaceutical Signs New Drug Supply Contract Worth 99.2 Billion KRW in Middle East Region
[Asia Economy Reporter Park Jihwan] Daewoong Pharmaceutical announced on the 15th that it has signed an export supply contract for the new drug for gastroesophageal reflux disease, 'Fexuprazan,' with Agras Healthcare for six Middle Eastern countries (Saudi Arabia, United Arab Emirates, Kuwait, Bahrain, Oman, Qatar).
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Russia Launches Large-Scale Nuclear Drills During Putin's Visit to China"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The contract amount is approximately 99.2 billion KRW. Daewoong Pharmaceutical stated, "The drug has not yet received approval in the contracted countries, and exports will proceed after local approval is completed."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
